portal vein thrombosis may be a negative prognostic marker of variceal bleeding in liver cirrhosis. Compared with conventional endoscopic and pharmacological therapy, transjugular intrahepatic portosystemic shunt may further improve the outcomes of portal vein thrombosis in liver cirrhosis with variceal bleeding.
Portal vein thrombosis may be a negative prognostic marker of variceal bleeding in liver cirrhosis. Compared with conventional endoscopic and pharmacological therapy, transjugular intrahepatic portosystemic shunt may further improve the outcomes of portal vein thrombosis in liver cirrhosis with variceal bleeding. However, the safety of transjugular intrahepatic portosystemic shunt remains uncertain in patients with portal vein thrombosis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
Transjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.
Non-selective beta blockers are the drugs for reducing the portal pressure.
Endoscopic therapy includes the endoscopic variceal band ligation
the First Affiliated Hospital, Air Force Medical University
Xi'an, Shaanxi, China
COMPLETEDXi'an International Medical Center Hospital
Xi'an, Shaanxi, China
RECRUITINGNanfang Hospital Affiliated to Southern Medical Univers
All-cause rebleeding or all-cause death
Cumulative incidence of all-cause rebleeding or all-cause death
Time frame: 3 years
Portal vein recanalization
Incidence of portal vein recanalization
Time frame: 3 years
Other decompensations of portal hypertension
defined as ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome
Time frame: 3 years
adverse events of treatment
Incidence of adverse events of treatment
Time frame: 3 years
Quality of life
quality of life assessed by the SF-36 health survey
Time frame: 3 years
Overall survival
Overall survival rate
Time frame: 3 years
Hepatocellular Carcinoma
Incidence of Hepatocellular Carcinoma
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Anticoagulation therapy includes heparin and warfarin.
Guangzhou, China
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
RECRUITINGProvincial Hospital Affiliated to Shandong University
Jinan, China
RECRUITINGThe First Affiliated Hospital of Nanchang University
Nanchang, China
RECRUITINGAffiliated Drum Tower Hospital of Nanjing University Medical School
Nanjing, China
RECRUITINGThe First Affiliated Hospital of Xinjiang Medical University
Ürümqi, China
RECRUITING